Correct Answer: D. Increases risk of squamous cell carcinoma
Barrett oesophagus is a premalignant condition characterized by replacement of the normal stratified squamous epithelium of the distal oesophagus with columnar epithelium containing intestinal-type mucosa (intestinal metaplasia). The critical discriminator here is the type of malignancy risk. Barrett oesophagus increases the risk of adenocarcinoma, NOT squamous cell carcinoma. The metaplastic columnar epithelium is prone to dysplasia and subsequent adenocarcinoma development (annual risk ~0.2–0.5% in non-dysplastic Barrett, higher in dysplastic forms). Squamous cell carcinoma of the oesophagus is associated with different risk factors—tobacco, alcohol, caustic ingestion, and achalasia—not Barrett oesophagus. In fact, Barrett oesophagus protects against squamous cell carcinoma because the squamous epithelium has been replaced. This is the key pathophysiological distinction that NBE tests: students often confuse "premalignant" with "increases all cancers," but Barrett specifically predisposes to adenocarcinoma via intestinal metaplasia, not squamous malignancy. Option D is therefore false and the correct answer.
Why the other options are wrong
A. Seen in 10% of individuals with symptomatic GERD — This is TRUE. Epidemiological studies show Barrett oesophagus occurs in approximately 10% of patients with chronic symptomatic GERD. In India, the prevalence is lower (~1–2% in endoscopy series) due to different GERD phenotypes and lower obesity rates, but the 10% figure reflects Western cohorts and is a standard teaching point. This statement is factually correct and must be excluded. B. Complication of chronic GERD — This is TRUE. Barrett oesophagus is a well-established complication of long-standing GERD. Chronic acid reflux causes injury to the squamous epithelium, triggering adaptive metaplasia to acid-resistant columnar epithelium. This is a direct consequence of chronic GERD and is universally accepted in pathology. This statement is correct and must be excluded. C. Intestinal metaplasia — This is TRUE. Intestinal metaplasia is the defining histological feature of Barrett oesophagus. The diagnosis requires columnar epithelium with goblet cells (intestinal-type mucosa) on biopsy. Without intestinal metaplasia, the condition is called columnar-lined oesophagus but not Barrett. This is the pathognomonic finding and must be excluded.
High-Yield Facts
- Barrett oesophagus → adenocarcinoma risk, NOT squamous cell carcinoma (which is tobacco/alcohol-related).
- Intestinal metaplasia with goblet cells is the histological hallmark required for diagnosis of Barrett oesophagus.
- Annual malignant transformation rate in non-dysplastic Barrett: 0.2–0.5%; in high-grade dysplasia: 5–10% per year.
- Prevalence in symptomatic GERD: 10% in Western populations; lower in India (1–2% in endoscopy cohorts).
- Risk factors for Barrett: chronic GERD, male sex, age >50, central obesity, smoking (paradoxically protective in some studies).
Mnemonics
BAD → ADC (Barrett → Adenocarcinoma) Barrett oesophagus → Adenocarcinoma (columnar metaplasia → glandular cancer). NOT squamous cell carcinoma. Use when you see 'Barrett + cancer risk' to lock in adenocarcinoma, not SCC. GERD-IM Rule GERD → Intestinal Metaplasia → Barrett. Chronic acid injury → adaptive columnar epithelium with goblet cells. Recall this when asked about Barrett's histology.
NBE Trap
NBE pairs "Barrett oesophagus" with "premalignant" to lure students into selecting any cancer-related option without discriminating between adenocarcinoma (correct) and squamous cell carcinoma (incorrect). The trap exploits the assumption that all premalignant conditions increase all cancer types.
Clinical Pearl
In Indian clinical practice, Barrett oesophagus is underdiagnosed due to lower GERD prevalence and limited endoscopic screening. When encountered, it mandates surveillance endoscopy with targeted biopsies every 2–3 years (non-dysplastic) or 3–6 months (dysplastic), as adenocarcinoma risk is real and prognosis is poor at advanced stages.
_Reference: Robbins and Cotran Pathologic Basis of Disease, Ch. 15 (Gastrointestinal Tract); Harrison's Principles of Internal Medicine, Ch. 287 (Disorders of the Gastrointestinal System)_